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Age-related macular degeneration (AMD) is one of the 
main causes of irreversible blindness in industrialized 
countries (1). It has been classified into a non-exudative 
or dry form and a neovascular or wet form. Visual 
prognosis is worst in patients affected by the neovascular 
form (2). 
Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which 
was approved by the FDA at the end of 2004, was the 
first anti-VEGF therapy for neovascular AMD (3). After 
approval of bevacizumab (Genentech/ Roche) for cancer 
therapy and in view of the suspected role of VEGF in wet 
AMD, systemic intravenous and, later, intravitreal 
bevacizumab began to be administered off-label to treat 
neovascular AMD (4). Ranibizumab (Genentech/ 
Novartis), a humanized monoclonal anti-Fab antibody, 
engineered to bind with high affinity to VEGF-A and 
inhibit all of its biologically active isoforms, was found to 
be an effective therapeutic agent for neovascular AMD. 
This was proven in two pivotal trials: the Minimally 
Classic/Occult Trial of the Anti-VEGF Antibody 
Ranibizumab in the Treatment of Neovascular Age-
Related Macular Degeneration (MARINA) and the Anti-
VEGF Antibody for the Treatment of Predominantly 
Classic Choroidal Neovascularization in Age-Related 
Macular Degeneration (ANCHOR) (5). Based on this 
evidence, ranibizumab was approved by the FDA in 2006 
as therapy for the treatment of wet AMD (6). 
Most AMD clinical trials of anti-VEGF agents, such as 
ANCHOR and MARINA, have excluded eyes of the 
patients with large pigment epithelial detachments 
(PEDs) or, if such eyes were included, further analysis of 
the PED response to treatment was not performed. 
Therefore, the management of PEDs in patients with 
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AMD is not clear and the usage of anti-VEGF in these 
cases remains controversial. 
Lommatzsch et al. retrospectively studied 328 patients 
with serous PEDs associated with wet AMD. They 
observed that bevacizumab or ranibizumab are 
significantly more efficient in improving vision and retinal 
thickness than pegaptanib alone or in combination 
treatment with intravitreal triamcinolone acetonide and 
photodynamic therapy (7). In contrast, Introini et al., in a 
retrospective study of 132 eyes, concluded that there is 
no effective therapy for PED secondary to AMD and that 
anti-VEGF treatment could achieve only stabilization of 
the disease with the high risk of RPE tear (8). On the 
other hand, Arora and McKibbin analyzed eyes of 19 
patients with vascularized and avascular PED, reporting 
that moderate visual loss was avoided in 95% of their 
patients and that 25% had a gain of 15 or more ETDRS 
letters, concluding that ranibuzumab is effective for both 
vascularized and avascular PED (9). In a prospective, 
comparative study, consisted of 15 patients, Arias proved 
that pegaptanib and bevacizumab were both an effective 
and safe therapeutic option for PEDs secondary to wet 
AMD (10). 
Inoue et al. were the first to evaluate the outcome of 
Ranibizumab treatment in patients with neovascular 
AMD according to the type of PED (11). This prospective 
study consisted of 56 patients (11 serous PED, 28 
fibrovascular PED, 7-mixed PED, and 10-haemorrhagic 
PED). Patients, treated with intravitreal ranibizumab 
according to the PrONTO study protocol, were followed-
up over a period of 12 months after the initial injection. 
Results demonstrated that ranibizumab was effective in 
stabilizing or improving vision in patients with PED, but 
with better results in patients with serous PED (11). Our 
Group observed last year the favorable effect of 
ranibizumab on serous and fibrovascular PEDs associated 
with neovascular AMD (12). According to our study, 
ranibizumab showed effectiveness in improving vision 
and macular anatomy in patients with fibrovascular or 
serous PED secondary to wet AMD, however the 
anatomical response of the PED to the treatment may 
not be correlated directly with the visual outcome. 
Two recent studies of the effect of aflibercept (Bayer 
Healthcare/ Regeneron Pharmaceuticals) on PEDs 
secondary to neovascular AMD have had promising 
outcomes. They concluded that aflibercept might be an 
effective alternative option for serous PED in neovascular 
AMD patients after bevacizumab and ranibizumab have 
previously failed (13) and that aflibercept may stabilize 
the visual acuity and improve the macular anatomy 
during the first 6 months of the treatment (14). 
At present, anti-VEGF therapy is widely used in 
ophthalmology. Diseases such as neovascular AMD, 
macular edema secondary to retinal vein occlusion, 
diabetic macular edema, choroidal neovascularization 
secondary to causes other than AMD, and corneal 
neovascularization are treated with anti-VEGF drugs (5, 
15-17). Regarding the efficiency of these drugs in the 
treatment of PEDs secondary to neovascular AMD, there 
is increasing evidence that they represent an effective 
and safe treatment approach that can stabilize or even 
improve the vision of patients and the macular anatomy. 
Larger studies in this field, especially about the efficacy 
of the newer anti-VEGF drug, aflibercept, are expected 
with great interest. 
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